MetaVia (NASDAQ:MTVA – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter.
MetaVia Price Performance
NASDAQ:MTVA opened at $1.59 on Thursday. The firm’s fifty day moving average price is $1.72. MetaVia has a 52 week low of $1.29 and a 52 week high of $5.30.
Analyst Upgrades and Downgrades
Separately, HC Wainwright assumed coverage on shares of MetaVia in a report on Monday, December 30th. They issued a “buy” rating and a $12.00 price objective for the company.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
See Also
- Five stocks we like better than MetaVia
- Insider Selling Explained: Can it Inform Your Investing Choices?
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Stock Analyst Ratings and Canadian Analyst Ratings
- Alphabet’s Officially In A Bear Market—Time To Buy?
- Why Invest in High-Yield Dividend Stocks?
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
